to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection

NCT06437951 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Erosive Gastroesophageal Reflux Disease

Interventions

DRUG: Fexuprazan Injection
DRUG: Fexuprazan Injection placebo
DRUG: Fexuprazan Injection_part 2
DRUG: Fexuprazan Injection_part 3
DRUG: Fexuprazan tablet

Sponsor

Daewoong Pharmaceutical Co. LTD.